Skip to main content
. 2016 Dec 15;8(2):155–160. doi: 10.1111/jdi.12593

Figure 2.

Figure 2

Lipid profiling by high‐performance liquid chromatography in low‐density lipoprotein receptor‐deficient mice with anagliptin (Ana). Plasma (a) very low‐density lipoprotein cholesterol (VLDL‐C), (b) low‐density lipoprotein cholesterol (LDL‐C) and (c) high‐density lipoprotein cholesterol (HDL‐C) concentrations after 4 weeks of anagliptin treatment. Data are shown as mean ± standard error of the mean (n = 10). *P < 0.05.